Dr. Juan Rodolfo Mella-Catinchi, MD

Dr. Mella-Catinchi practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Mella-Catinchi's NPI, 1952561763, was assigned on June 15, 2008. Dr. Mella-Catinchi graduated from Boston University School Of Medicine in 2008. Dr. Mella-Catinchi holds Florida license ME145386.

Dr. Mella-Catinchi's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Mella-Catinchi's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Mella-Catinchi is also affiliated with Jackson Memorial Hospital. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Mella-Catinchi to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mella-Catinchi practices, 3 sites in all. Vendor and product names are available with a free account.

Plastic and reconstructive surgery is Dr. Mella-Catinchi's primary specialty in the NPI Registry, under taxonomy code 2086S0122X. Dr. Mella-Catinchi is board certified in plastic surgery by the American Board of Plastic Surgery. Dmand AI has Dr. Mella-Catinchi's licenses on file in 4 states: Florida, Maine, Texas and Massachusetts.

Dmand AI lists breast reconstruction, breast surgery and lymphedema among the conditions Dr. Mella-Catinchi treats.

CMS data shows 28 Medicare services from Dr. Mella-Catinchi across 1 procedure code in 2024, all of them office visits, for 45 Medicare patients. Medicare paid $1,408 for them. Every service was in an office.

CMS counts 45 Medicare patients who saw Dr. Mella-Catinchi in 2024. The largest group is 65 to 74, with 27 patients. 75% of them have high cholesterol, and 64% have cancer. 27% are also on Medicaid. Their average risk score is 1.65, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mella-Catinchi's median patient age at 63, with 89% women.

In 2024, Dr. Mella-Catinchi wrote 28 Medicare Part D claims for 14 patients. 100% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $103 in total drug cost. In 2021, CMS named 16 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Mella-Catinchi for performance year 2024, reported as part of a group. Dr. Mella-Catinchi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mella-Catinchi as offering telehealth. CMS counts 11 procedures of mastectomy by Dr. Mella-Catinchi, more than 64% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 1 paper to Dr. Mella-Catinchi in 2025. Dr. Mella-Catinchi's most frequent co-authors are John Christopher Oeltjen, MD, PhD, Devinder Singh, MD and Cristiane Takita, MD.

CMS Open Payments shows 74 general payments to Dr. Mella-Catinchi from 18 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 76% of the total. AxoGen paid the most, $3,419.

Dr. Mella-Catinchi graduated from Boston University School Of Medicine in 2008. Dr. Mella-Catinchi is a member of ACS.

Dr. Mella-Catinchi is in network with 10 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.